Could blood pressure pills boost stomach cancer treatment?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Voluntarily sign the informed consent form; Aged 18-75 years; ECOG performance status 0-1; Either sex; Patients with a standardized histopathological diagnosis of gastric adenocarcinoma from the primary gastric lesion via endoscopic biopsy, according to the 15th edition of the Japanese Classification of Gastric Carcinoma (2017); Patients judged by the treating physician to require preoperative immune checkpoint inhibitor therapy, followed by potentially curative gastrectomy; Meet the diagnostic criteria for hypertension according to the 2023 Chinese Guidelines for the Management of Hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, or a previous diagnosis of uncontrolled hypertension), with an indication for beta-blocker use; Deemed by a specialist to have no contraindications for beta-blocker use and can use beta-blockers for antihypertensive therapy. Exclusion Criteria: HER2-positive or microsatellite instability-high (MSI-H)/dMMR gastric cancer confirmed by immunohistochemistry; Active autoimmune disease requiring continuous immunosuppressive therapy or history of transplantation; Currently receiving systemic immunosuppressive medication: If a patient is currently using corticosteroids, the corticosteroid dose must be ≤ equivalent of prednisone 10 mg daily; History of (non-infectious) pneumonitis/interstitial lung disease requiring treatment; Concurrent infection with human immunodeficiency virus (HIV); Pregnant or breastfeeding women; History of psychiatric disorders; Concurrent other malignancies or severe organ dysfunction; Presence of contraindications for beta-blocker use (e.g., severe bradycardia, uncontrolled depression, unstable angina, uncontrolled heart failure (Class III or IV), hypotension (systolic blood pressure \<100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, etc.); Refractory hypertension; Judged by the investigator as not meeting the inclusion criteria for this study